NCT02471469View on ClinicalTrials.gov

Personalizing Enzalutamide Therapy by Understanding the Relation Between Tumor mRNAs, miRNAs and Treatment Response

CompletedOBSERVATIONAL
Enrollment

40

Participants

Timeline

Start Date

October 31, 2015

Primary Completion Date

February 13, 2019

Study Completion Date

August 1, 2019

Conditions
Metastatic Castration Resistant Prostate Cancer
Interventions
DRUG

Enzalutamide, 160mg, 40 mg soft capsules, once daily

Exclusively determine pharmacokinetics and pharmacodynamics of enzalutamide for the indication according to the drug label

Trial Locations (3)

Unknown

Jeroen Bosch Ziekenhuis, 's-Hertogenbosch

Canisius Wilhelmina Ziekenhuis, Nijmegen

6500HB

Radboud UMC, Nijmegen

All Listed Sponsors
collaborator

Astellas Pharma Europe B.V.

INDUSTRY

lead

Radboud University Medical Center

OTHER

NCT02471469 - Personalizing Enzalutamide Therapy by Understanding the Relation Between Tumor mRNAs, miRNAs and Treatment Response | Biotech Hunter | Biotech Hunter